This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

About CRESEMBA®About CRESEMBA®Meet CRESEMBA®CRESEMBA® in the ICUCRESEMBA® in ActionEfficacy EfficacyInvasive AspergillosisEfficacyGuidelines MucormycosisEfficacyGuidelinesSafetySafetyTolerabilityInvasive AspergillosisMucormycosis Safety ProfileSafety ProfileDosingDosingSimple DosingLinear PKs, Low Variability and TDMPractical ConsiderationsReal-world DataReal-world DataReal-world EffectivenessReal-world SafetyResourcesResourcesSummary of Prescribing InformationEventsMaterialsVideos

The latest second-generation azole1–3 designed to help your patients see through the storm

A treatment of choice for a growing number of patients4,5

  

Since launching in 2015, CRESEMBA® has helped more than 90,000 patients worldwide:4,5 

 >91,000 patients treated4 Marketing authorisation in 46 countries5 >2.5 million patient days5 KickerComing Soon...The latest second-generation azole1–3

CRESEMBA®: specifically designed to facilitate IV administration, reducing the risk of renal toxicity associated with other azoles1,2,6,7

 Coming Soon...LoadingThe latest second-generation azole1–3

CRESEMBA®: specifically designed to facilitate IV administration, reducing the risk of renal toxicity associated with other azoles1,2,6,7

 Watch the MoA Video Loading The only azole approved for both invasive aspergillosis and mucormycosis1,2,6,8

CRESEMBA® offers an extended antimould spectrum across Aspergillus and Mucorales1,3,9–12

CRESEMBA® provides efficacy you can rely on even before a definitive diagnosis13,14

 View Data Suitable for the needs of your patients2,6,8,14 Compared with other azoles, CRESEMBA® has fewer drug–drug interactions, more predictable PKs, and better renal and hepatic tolerability, allowing it to be used in a variety of patients1,13–16

The flexibility of CRESEMBA® could help you manage your patient’s invasive fungal infection while keeping focus on their underlying condition1,14,15,17

 

 View Flexibility

Example

Designed to overcome key azole limitations1,2,6–8 CRESEMBA® brings you IV and oral formulations that overcome important azole limitations7

The oral formulation has high bioavailability (98%), allowing for interchangeable IV and oral dosing1

Unlike other IV azoles, CRESEMBA® does not require potentially nephrotoxic excipients such as cyclodextrin and betadex sulfobutyl ether sodium (SBECD)1,2,6,7

 

 View Dosing 

Further resources

 

Coming Soon...

KickerHeader of this CTA card goes here

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim…

Button Loading CRESEMBA® IV reconstitution, dilution and administration Watch Video IV administration leaflet​​​​​​​ View Leaflet Patient booklet​​​​​​​ View Booklet

ICU, intensive care unit; IV, intravenous; PK, pharmacokinetic.


Prescribing Information:
CRESEMBA® (isavuconazole)

References:

Adapted from Local Product Document of CRESEMBA® (Isavuconazole) version LPDCRE052021.Adapted from Local Product Document of VFEND® (Voriconazole) version LPDVRC022022.Miceli MH and Kauffman CA. Clin Infect Dis 2015;61(10):1558–1565.Basilea. CRESEMBA® Periodic Safety Update Report 9. September 2020. DOF.Basilea. CRESEMBA® Global Core Dossier. 2020. DOF.Posaconazole Summary of Product Characteristics.Donnelley MA et al. Infect Drug Resist 2016;9:79–86.Itraconazole Summary of Product Characteristics.Arendrup MC et al. Antimicrob Agents Chemother 2015;59(12):7735–7742.Guinea J et al. PLoS One 2017;12(6):e0179136.Sabatelli F et al. Antimicrob Agents Chemother 2006;50(6):2009–2015.Amphotericin B liposomal Summary of Product Characteristics.Maertens JA et al. Lancet 2016;387(10020):760–769.Marty FM et al. Lancet Infect Dis 2016;16(7):828–837.Natesan SK and Chandrasekar PH. Infect Drug Resist 2016;9:291–300.Kaindl T et al. J Antimicrob Chemother 2019;74:761–767.Perfect JR. Nat Rev Drug Discov 2017;16(9):603–616.

PP-CRB-IND-0472 July 2022


PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-CRB-IND-0472

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023